New Triple Drug Combo Shows Promise Against Advanced Prostate Cancer
Innovative treatment combining three powerful drugs achieved 85% progression-free survival at one year in high-risk patients.
Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
318 articles
Innovative treatment combining three powerful drugs achieved 85% progression-free survival at one year in high-risk patients.
Phase I trial shows NT-I7 safely increases lymphocyte counts and expands cancer-fighting T cells in high-grade glioma patients.
Researchers find new therapeutic potential in existing medication for treating challenging desmoid tumors.
Tislelizumab plus anlotinib achieved promising results in treating advanced pulmonary sarcomatoid carcinoma with manageable side effects.
Combining CSF1R inhibitor with chemotherapy enhanced immune response and improved outcomes in triple-negative breast cancer patients.
Breakthrough combination therapy challenges current standard treatment for PD-L1-positive lung cancer patients.
New AI model analyzes standard pathology slides to predict cancer recurrence risk, potentially replacing expensive genetic tests.
Bireociclib plus fulvestrant significantly improved outcomes in advanced hormone-positive breast cancer patients.
A pediatric oncologist reflects on living with multiple cancers throughout his career and life.
Leading epidemiologists respond to concerns about methodological limitations in research linking ultraprocessed foods to cancer risk.
New research reveals obesity prevention as an underutilized strategy that could significantly reduce cancer risk across multiple types.
New PRIME model identifies high-risk patients using standard health records, achieving 75% accuracy in predicting pancreatic cancer.